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Abstract The objective of this double-blind, randomized, placebo-controlled, parallel-group study was to compare the 
pharmacodynamic effects and safety of beclometasone dipropionate (BDP) given by nebulization or metered-dose 
inhalation in adult patients with asthma. Following a I -weel< run-in period, 40 patients, aged 18-60 years, with intermittent 
bronchial asthma were randomized to one of four treatment groups for 3 weel<s (n= IO in each group): beclometasone 
dipropionate (BDP) suspension for nebulization I600 pgday’ b.i.d. via a nebulizer; BDP suspension for nebulization 
3200 pg day-1 b.i.d. via a nebulizev; BDP 800 pg day-1 b.i.d. via a metered-dose inhaler (MDI) plus spacev; or placebo. At 
study end, comparable effects were reported for all active treatment groups on the primary pharmacodynamic endpoint 
of FEV, in response to methacholine bronchial provocation testing, with a statistically significant improvement shown in 
the BDP 3200 pg da>rl suspension for nebulization group compared with pre-treatment for other parameters, including 
FEV, and peak expiratory flow rates. All treatments were comparable. All treatments were equally well tolerated. No 
significant effects on cortisol levels were reported in any of the treatment groups. 
0 2003 Elsevler Science Ltd 
INTRODUCTION 
The aim of treatment with nebulizers is to deliver a 
therapeutic dose of the drug in the form of respirable 
particles within a short period of time, usually 
5-l 0 minutes (I). Efficient nebulizer therapy requires a 
device that repeatedly and quickly delivers sufficient drug 
to the site of the action and with minimal wastage. 
Nebulizers used in aerosol drug delivery produce a 
polydisperse aerosol where most of the drug released is 
contained in particles l-5 urn in diameter. Most 
nebulizers use compressed air for administration, but 
some use ultrasonic energy (2,3). 
It has been reported that beclometasone dipropionate 
(BDP) suspension for nebulization 800 ug, delivered via a 
nebulizer, yields a respirable dose of 195 ug, which is 
approximately double the respirable dose obtained with 
BDP pressurized MDI 250 ug (95 ug), thus suggesting that 
in order to attain equivalent in-vivo performance the 
nebulizer product would be expected to be used in a dose 
ratio of 2: I with respect to the pressurized inhaler (4). 
The purpose of this clinical pharmacology study was to 
establish a dose-response relationship for a new 
formulation of BDP suspension for nebulization by 
comparing the efficacy and safety of two different dosages 
administered via a nebulizer with those of a standard 
dose of BDP administered via an MDI plus spacer (BDP 
MDI) in adults with intermittent bronchial asthma, using 
the methacholine bronchoprovocation test as the 
primary pharmacodynamic variable and the measurement 
of FEV, and peak flow as secondary endpoints. 
MATERIALS AND METHODS 
Male and female patients, aged 18-60 years, with a clinical 
diagnosis of bronchial asthma of intermittent severity (as 
defined according to the GINA classification), predicted 
forced expiratory volume in I second (FEV,) of 2 80% at 
screening after at least an 8-h washout of inhaled p- 
agonist, positive response to the bronchial provocation 
test to methacholine (defined as a decrease of 20% in 
FEV, with inhalation of I8 mg ml-l), and body mass 
index of 18-35 kg m-z, and who were ambulatory, were 
eligible to participate in the study. Patients with a history 
of clinically significant major disorders or who received 
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an investigational drug in the previous 3 months were 
excluded from the randomization. 
Study design 
This was a 4-week, double-blind, randomized, placebo- 
controlled study undertaken in four parallel groups at 
two centres. Following a l-week run-in period, patients 
who met study entry criteria were assigned to one of the 
four treatment groups for an active treatment period of 
3 weeks: BDP suspension for nebulization I600 pg day-’ 
b.i.d. (Clenil-A@, Chiesi Farmaceutici SpA, Italy), plus 
placebo suspension for nebulization twice-daily, plus two 
puffs twice-daily of placebo spray; BDP suspension for 
nebulization 3200 I-18 day-’ b.i.d., plus two puffs twice- 
daily of placebo spray; BDP spray 800 .ug day-1 b.i.d. 
(Becotide@, Allen & Hanburys, U.K.) (two puffs twice- 
daily), plus placebo suspension for nebulization twice- 
daily; or placebo suspension for nebulization twice-daily, 
plus two puffs twice-daily of placebo spray. The 
suspension for nebulization was administered using the 
air compression Pari LC Plus@ nebulizer (Pari Turbo 
Boy@) (Pari, Germany), and the spray was given via an 
MDI plus spacer (Volumatic@, Allen & Hanburys, U.K.). 
Theophyllines, inhaled (other than the test BDP) or oral 
corticosteroids, and long-acting inhaled P-agonists were 
excluded.The use of short-acting inhaled &-agonists at 
the same dosage used previously, inhaled or oral sodium 
cromoglycate or nedocromil sodium at a constant 
dosage during the study period, oral P-agonists, anti- 
cholinergics, antihistamines, and leukotriene antagonists 
was permitted. Patients were assessed at clinic visits 
before and postrandomization. 
Bronchoprevention testing was performed at baseline 
and after 3 weeks of study medication. Increasing 
concentrations of methacholine from 0.0625 mg ml-1 to 
I28 mg ml-’ were administered via an air compressor- 
driven nebulizer (Pari LC Plus@), doubling the 
concentration at each step. FEV, was measured following 
each increase in methacholine dose. FEV,, measured 
using the Vitalograph-compact spirometer, physical 
examination, vital signs, temperature, laboratory safety 
tests, and random morning serum cortisol levels were 
assessed at baseline and at the end of the treatment. 
Morning peak expiratory flow rate (PEFR) was measured 
daily by patients using a Mini-Wright@ peak flow meter 
(Clement Clarke International, Essex, U.K.) and the best 
of three measurements recorded on a diary card. The 
institutional review board for each treatment centre 
approved the protocol, and written informed consent 
was obtained from the patients. 
Assessments 
The primary pharmacodynamic endpoint was the change 
in FEV, in response to methacholine bronchial provoca- 
tion testing, by determining the change in concentration 
of methacholine that resulted in 20% reduction in FEV, 
from baseline (PC,,). Secondary pharmacodynamic 
variables were FEV,, morning PEFR, and PEFR variability. 
Safety parameters were random morning cortisol levels, 
physical examination, vital signs, temperature, various 
laboratory safety tests, and adverse events. 
Statistical analysis 
No formal power calculations were undertaken for this 
study since it is an efficacy study and hence there should 
be adequate data for power.The sample size was based on 
previous data from similar studies involving comparisons 
of inhaled steroids in mild asthmatics using methacholine 
bronchial provocation as a method to determine efficacy. 
Statistical analysis of the bronchial provocation test was 
carried out by calculating the mean ratio of PC,, values at 
study end/PC,, values pretreatment, of predicted FEV, by 
calculating the difference in mean values between baseline 
and study end, of morning PEFR and PEFR variability by 
calculating the difference between mean values at the start 
of run-in - pretreatment and poststudy, and of random 
cortisol concentrations by calculating the difference 
between mean values at baseline and study end. Within- 
and between-treatment comparisons were undertaken 
using one- or two-sample t tests. 
RESULTS 
Patient population 
In total, 40 patients were randomized: IO to the BDP 
I600 pg day-’ nebulization group, IO to the BDP 
3200 pgday’ nebulization group, IO to the BDP MDI 
group, and IO to the placebo group. All enrolled patients 
completed the trial. Assessment of safety was based on 
all randomized patients. Patient demography at baseline 
was comparable for the four groups in the randomized 
population (Table I). 
Evaluation of efficacy: 
bronchial provocation test 
Increases in PC,, were seen with all active treatment 
groups at the end of the 3-week treatment period 
compared with pretreatment, with the improvement 
reported in the BDP 32OO~gday’ nebulization group 
being statistically significant. However, there were no 
statistically significant differences in PC,, between any of 
the active treatment groups at the end of the study.The 
mean study end/pretreatment bronchoprovocation test 
ratio for each treatment group is shown in Figure I. 
Evaluation of efficacy: 
Other measures of pulmonary function 
Similar changes in mean predicted FEV, values were 
observed in all active treatment groups at treatment end 
when compared with baseline. 
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Changes in morning PEFR were of limited clinical 
significance because patients were mild asthmatics with 
high baseline PEFR values and statistically significant 
differences were found between the groups prior to 
treatment (Table 2). 
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Both of the BDP nebulization groups produced similar 
changes in mean PEFR variability at study end vs 
pretreatment, and an increase was shown in the BDP 
MDI group that was statistically significant. This 
unexpected latter finding may be explained by the fact 
that the group size was not powered. 
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Evaluation of safety 
Safety data showed that all active treatments were well 
tolerated. During the treatment period, 23 patients (five 
patients each in the BDP I600 pg day’ nebulization, BDP 
MDI, and placebo groups, and seven in the BDP 
3200 pg day’ nebulization group) reported adverse 
events.The number of adverse events reported was 82: 13, 
34, 19, and I5 in the BDP I600 pg day-’ nebulization, BDP 
3200 pg day-l nebulization, BDP MDI, and placebo groups, 
respectively, and these tended to be mild to moderate in 
severity and were most commonly headache and sore 
throat. Of these adverse events, I6 were considered to be 
related to treatment, with seven of these occurring in 
placebo-treated patients. No patients were withdrawn 
from the study due to the adverse events reported. 
FIGURE I. Mean values for study end/pretreatment broncho- 
provocation test ratio (standard deviation) in the randomized 
population of adults with intermittent bronchial asthma after 
3 weel<s of treatment with beclometasone dipropionate given by 
nebulization or metered-dose inhalation, or placebo. 
were reported in any of the groups during the treatment 
period for vital signs or temperature, and none of the 
abnormal findings noted for physical examination or 
laboratory safety tests was considered to be of relevance 
with respect to the study or study treatments. 
DISCUSSION 
In addition, no notable changes in mean random This study was designed to evaluate the efficacy and 
morning cortisol levels were seen in any of the groups at safety of two different dosages of a new formulation of 
the end of the treatment period vs baseline, and no BDP given via a nebulizer and a standard dose of BDP 
significant between-treatment differences were found given using an MDI plus spacer as a 3-week treatment for 
(Figure 2). Moreover, no clinically significant changes intermittent bronchial asthma in adult patients. 
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FIGURE 2. Mean values for random morning cortisol levels k 
standard deviation in the randomized population of adults with 
intermittent bronchial asthma at baseline and after 3 weeks of 
treatment with beclometasone dipropionate given by 
nebulization or metered-dose inhalation, or placebo. 
Several studies have compared the efficacy of 
budesonide given via nebulizer and MDI. In a study of 2 I 
adult patients with asthma, budesonide suspension 
delivered from a nebulizer activated during inspiration 
exhibited a dose-dependent effect, apparently equipotent 
to the MDI administration as evaluated from daily peak 
expiratory flow (PEF) measurements and symptom 
scoring (5). Continuous nebulization of budesonide in I8 
schoolchildren with bronchial asthma similarly showed a 
dose-dependent improvement of lung function and 
symptom score, though in a I :2 potency ratio compared 
with MDI administration (6). More recently, a study 
involving 26 adult asthmatics compared budesonide 
0.8 mg twice-daily administered by pMDl with spacer 
and budesonide I mg and 4 mg twice-daily administered 
by a Pari Inhaler Boy jet nebulizer, activated only during 
inspiration.The total mass output was similar from the 
two devices, but their fraction of small particles differed 
by a factor of 2 in favour of pMDI. Effect was evaluated 
from daily home measurements of PEF need of p2- 
agonist, and symptom scores.A consistent trend showed 
the nebulizer treatment to be at least as efficient as the 
pMDl plus spacer treatment. In actual fact, the apparent 
order of effect was 4 mg nebulized suspension treatment 
2 I mg nebulized suspension treatment > 0.8 mg pMDl 
with spacer treatment (7). 
The primary objective of this study was to determine 
the effect of the treatments on FEV, in response to 
methacholine challenge, with the bronchial provocation 
test ratio being the main efficacy variable.The results of 
the methacholine test expressed as a ratio of PC,, after 
3 weeks’ treatment compared with the PC,, value 
before treatment, although not statistically significant 
(probably due to the small sample size in each treatment 
group), demonstrated a protection of bronchial hyper- 
reactivity with the different types of active treatment, a 
significant dose effect at the highest dosage level of 
nebulized BDP and equivalent effects with BDP 
I600 pg day-l nebulization and BDP MDI 800 pg day’. 
The data showed that only nebulized BDP 3200 pg day’ 
produced a significant change in PC,, between 
pretreatment and study end, but a between-treatment 
analysis indicated that there was no treatment-related 
difference when compared with placebo. 
The study was intended as a comparison of efficacy on 
bronchial reactivity to confirm a dose response and that 
the 2:1 ratio of nebulized BDP to BDP MDI was 
appropriate. The within-treatment difference observed 
with BDP nebulization 3200 pgday-1 compared with 
baseline is supportive of a trend towards a dose 
response.The absence of between-treatment differences 
indicates that the proposed 2: I ratio is appropriate, and 
that BDP nebulization I600 pg day-’ is indistinguishable 
from BDP MDI 800pgday1. The increased systemic 
exposure would justify use of BDP 3200 pgday-1 
nebulization in subjects with more severe asthma. 
All three active treatments were equally well 
tolerated, as demonstrated by examining a number of 
safety parameters. Furthermore, morning serum cortisol 
levels remained within normal ranges and, although not 
statistically significant (probably on account of the small 
number of patients in each group), the results indicated 
a dose effect with nebulized BDP and an absence of any 
detrimental effect with the lower dose (I 600 pg day’). 
In conclusion, this study demonstrates that BDP 
suspension for nebulization l600- and 3200 pg day’ 
given by a nebulizer and BDP spray 800 pg day-1 given via 
an MDI plus spacer have equivalent effects with respect 
to the bronchoprovocation test, with a good safety and 
tolerability profile. 
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